CollPlant
Develops recombinant human collagen (rhCollagen) and BioInk for 3D bioprinting of tissues and organs, enabling regenerative medicine applications.
- CEO / Founder
- Yehiel Tal
- Team Size
- 51-200
- Stage
- Public
- Total Funding
- $10.4M
- Latest Round
- Private Equity
- Key Investors
- Alpha Capital; Martin Schlaff
Technology & Products
Key Products
BioInk; rhCollagen; Collage (3D bioprinting products); Orthobiologics; Wound care products
Technological Advantage
Proprietary plant-based recombinant human collagen production, protected by patents, offers a unique source of human collagen for bioprinting and regenerative medicine.
Differentiation
Value Proposition
Provides patented plant-derived recombinant human collagen and BioInk that enable 3D bioprinting of functional tissues and organs, reducing reliance on animal-derived collagen and improving biocompatibility.
How They Differentiate
Unlike competitors that use animal-derived or synthetic collagen, CollPlant produces recombinant human collagen from plants, offering superior biocompatibility and scalability.
Market & Competition
Target Customers
Medical device companies, bioprinting companies, and healthcare product developers
Industry Verticals
Medical; Biotechnology; Pharmaceuticals
Competitors
BICO (Cellink); 3D Systems (Allevi); Humabiologics
Growth & Milestones
Growth Metrics
Full year 2023 revenues of $10.1 million, up from $5.9 million in 2022 (71% growth); 2024 Q1 revenue $1.3 million; collaborations with major bioprinting companies; operating expenses ~$20.5 million in 2023; cash position $22.5 million as of March 2024.
Major Milestones
Founded in 2004; IPO on NASDAQ in 2016; Renamed to CollPlant Biotechnologies in 2019; Received $10M milestone from AbbVie
Notable Customers
United Therapeutics (collaboration for 3D-printed lung scaffolds); Advanced Regenerative Manufacturing Institute (ARMI); Stratasys (collaboration for bioprinting); 3D Systems (collaboration for bioprinting); Mildred Scheel School of Oncology (research collaboration)